espite impressive changes at the organ, tissue and cellular level in myocardial reverse remodeling with left ventricular assist device support, reprogramming the presumed "endstage" human heart toward the nonfailing phenotype has not been convincingly demonstrated (1-5). Many have questioned the possibility of achieving sustained myocardial "recovery" using our current technology, leading to a call for further investigation by a recently gathered National Heart, Lung, and Blood Institute task force (6). Metabolic adaptations have been reported in the calorie-restricted, exercising, ischemic, and failing myocardium-and recently, the lipidomic signature of the end-stage failing, nondiabetic human heart has revealed rarefied lipid stores and evidence for a newly discovered shift to ketones as an alternative energy fuel (7-10).
demonstrates decreased levels of glucose-1-phosphate and glucose-6-phosphate in the endstage failing myocardium, which is indicative of a decreased utilization of glucose, and is consistent with decreased glycolysis in advanced heart failure.
The importance of this finding, coupled with the demonstration that with mechanical unloading there is an increase in the levels of glycolytic metabolites is extremely important, insofar as it shows that there is not a uniform shift to increased glucose metabolism across the broad spectrum of heart failure. Instead, Starting with this important contribution by Diakos et al. (11) , further understanding of the metabolic phenotypes resulting from the reversal of heart failure is likely to enhance, not only our rate of myocardial recovery, but the durability after explantation that may be the real target in our efforts to reprogram the failing human heart.
